Skip to main content
. 2023 Aug 1;42(1):28–55. doi: 10.1007/s11604-023-01476-1

Table 5.

Summary of representative studies on 18F-FDG PET/CT radiomics-based machine learning analyses in abdominal tumors

Authors Years Tumor type Aim Sample size Constructed ML models Core ML algorithm Best ML model Validation Resultsa
Differentiating benign from malignant tumors
 Zhang et al. [102] 2019 Pancreatic tumor AIP vs. PDAC n = 251

CT radiomics-based model

PET radiomics-based model

Combined model

SVM Combined model Internal validation (cross-validation) Accuracy: 0.850
 Wei et al. [103] 2023 Pancreatic tumor AIP vs. PDAC n = 112

CT radiomics-based + PET radiomics-based model

DL feature-based model

Multidomain fusion model (radiomics + DL features)

VGG11 DL algorithm Multidomain fusion model Internal validation (cross-validation) Accuracy: 0.901
Predicting tumor characteristics or stage
 Xing et al. [104] 2021 PDAC Pathological grade n = 149

CT radiomics-based model

PET radiomics-based model

Combined model

XGB Combined model Training and validation cohorts AUC: 0.921
 Jiang et al. [105] 2022 HCC or ICC MVI HCC: n = 76; ICC: n = 51

Clinical model

CT radiomics-based model

PET radiomics-based model

Combined optimal PET and CT radiomics-based model

Combined best clinical, PET radiomics-based, or CT radiomics-based model

RF Combined best clinical and PET feature-based model Training and validation cohorts

AUC for HCC: 0.88

AUC for ICC: 0.90

 Liu et al. [106] 2021 Gastric cancer LNM n = 185

CT radiomics-based model

PET radiomics-based model

Combined model

Adaboost Combined model Training and validation cohorts Accuracy: 0.852
 He et al. [107] 2021 Colorectal cancer LNM n = 199 Combined CT + PET radiomics-based model XGB Training and validation cohorts Accuracy: 0.7636
 Li et al. [108] 2021 Colorectal cancer MSI n = 173 Combined clinical + CT radiomics-based + PET radiomics-based model alone Adaboost Training and validation cohorts AUC: 0.828
Predicting treatment response or survival
 Toyama et al. [109] 2020 Pancreatic cancer 1-year survival after RT, CRT, or surgery n = 161 PET radiomics-based model alone RF

Internal validation

(cross-validation)

HR for GLZLM_GLNU: 2.0
 Liu et al. [110] 2023 Gastric cancer

HER2 status

Progression after surgery

n = 90

Combined clinical + CT radiomics-based + 

PET radiomics-based model

Adaboost Training and validation cohorts

Accuracy for HER2: 0.833

Accuracy for progression: 0.778

 Lv et al. [111] 2022 Colorectal cancer Recurrence-free survival after surgery n = 196

Clinical model

CT radiomics-based model

PET radiomics-based model

Combined model

RSF Combined model Training and validation cohorts

C-index for all patients: 0.780

C-index for patients with stage III disease: 0.820

 Shen et al. [112] 2020 Rectal cancer pCR after NCRT n = 169 PET radiomics-based model alone RF Internal validation Accuracy: 0.953
 Agüloğlu et al. [113] 2023 Metastatic rectal cancer 2-year OS n = 62 PET radiomics-based model alone RF

Internal validation

(cross-validation)

AUC: 0.843

AIP autoimmune pancreatitis, AUC area under the receiver operating characteristic curve, C-index concordance index, CRT chemoradiotherapy, DL deep learning, GLNU gray-level non-uniformity, GLZLM gray-level zone length matrix, HCC hepatocellular carcinoma, HER2 human epidermal growth factor receptor, HR hazard ratio, ICC intrahepatic cholangiocarcinoma, LNM lymph node metastasis, ML machine learning, MSI microsatellite instability, MVI microvascular invasion, NCRT neoadjuvant chemoradiotherapy, OS overall survival, pCR pathological complete response, PDAC pancreatic ductal adenocarcinoma, RF random forest, RSF random survival forest, RT radiotherapy, SVM support vector machine, XGB gradient tree boosting

aPerformance only presents the result of the best machine learning model